PrecisionLife Ltd
R&D
- Website
- https://www.precisionlife.com
- Membership category
- Corporate
Unit 8B Bankside, Hanborough Business Park, Witney, OX29 8LJ, United Kingdom
PrecisionLife Ltd at a glance
About PrecisionLife Ltd
PrecisionLife is a clinical stage AI-led precision medicine company that focuses on chronic diseases. We use our novel patient stratification approach to find more causal and predictive signal and expand knowledge of (known and novel) disease mechanisms and drug response. This enables us to link biological mechanism to the patient subtype for whom it is relevant.
Our approach is scalable and powered by over 35 data access agreements. We have undertaken over 50 chronic disease studies and have hundreds of thousands of proprietary insights in our DiseaseBank repository. We have completed studies in CNS, autoimmune, cardiovascular, respiratory, and metabolic diseases to find better treatment options for patients with unmet medical needs.
Our capability is built on a unique, patented analytical approach that can detect 10X more disease signal in patient datasets 10% of the size required by GWAS or established statistical methods. Our signals replicate 9X greater than leading GWAS studies.
Our proprietary insights are reduced to practice as saliva or blood based genotypic tests that can be deployed on proprietary platforms that are operated in CLIA CAP laboratories around the world.
We support biopharma partners in the following ways:
Healthcare
Developing a pipeline of novel diagnostics that assess individuals disease risks and specific mechanisms underpinning disease (Mechanostic). The clinical report can recommend treatments that are consistent with the mechanisms of action present in the patient.
Drug discovery
De-risking target evaluation and selection with knowledge of causal genetic, mechanistic explanation of observed clinical phenotype, mechanistic prevalence, match to TPP and secondary indication potential.
Drug development
We improve probability of success through indication prioritisation; use of mechanistic patient stratification biomarkers as inclusion criteria to enable design of smaller, faster, more targeted clinical trials and support of trials in flight through creating genotype digital twins that can be used to monitor enrolled populations, and scenario planning. We are able to undertake retrospective study analysis to explain unexpected response profiles and identify mechanisms of participant response.
Portfolio strategy
We identify label extension opportunities to maximise revenue potential of existing assets, and develop complementary diagnostics to support prescribing of product to patients that have the propensity to respond to products.
Our insights, mechanism-based biomarkers and analytical approach are available for partnering where we can improve our partners probability of success.
